Details
Stereochemistry | ACHIRAL |
Molecular Formula | Fe |
Molecular Weight | 58.9349 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
[59Fe++]
InChI
InChIKey=CWYNVVGOOAEACU-AKLPVKDBSA-N
InChI=1S/Fe/q+2/i1+3
Molecular Formula | Fe |
Molecular Weight | 58.9349 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/mmx/ferrous-citrate-fe-59.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2330802 | https://www.ncbi.nlm.nih.gov/pubmed/5098207
Sources: https://www.drugs.com/mmx/ferrous-citrate-fe-59.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2330802 | https://www.ncbi.nlm.nih.gov/pubmed/5098207
Ferrous citrate Fe 59 is indicated, by intravenous administration, to determine various parameters of the kinetics of iron metabolism, including plasma iron clearance, plasma iron turnover rate, and the utilization of iron in new red blood cells. The values of serum iron obtained from these studies provide diagnostic information in patients with anemias. Ferrous citrate Fe 59 is also useful to assess the role of the spleen in red blood cell production and destruction, and thus to help determine the advisability of splenectomy. Also, organ uptake measurements are used to measure the sites of red cell production (or lack thereof) in extramedullary erythropoiesis in myeloproliferative disorders. Iron from ferrous citrate is bound to plasma protein (transferrin) and carried to the blood-forming organs where it is utilized to form hemoglobin or is deposited in the reticuloendothelial cells of the liver and spleen. The amount of radioactive iron absorbed, transported, stored, utilized, and excreted can then be measured by the periodic collection of blood specimens and external counting.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17379104 |
Diagnostic | FERROUS CITRATE FE 59 Approved UseIt was used for anemia diagnosis. Launch Date1973 |
||
Diagnostic | FERROUS CITRATE FE 59 Approved UseUnknown Launch Date1973 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/ferrous-citrate-fe-59.html
Intravenous or oral, 0.185 to 0.555 megabecquerel (5 to 15 microcuries).
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:38:42 GMT 2023
by
admin
on
Sat Dec 16 09:38:42 GMT 2023
|
Record UNII |
5634T58D89
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5634T58D89
Created by
admin on Sat Dec 16 09:38:42 GMT 2023 , Edited by admin on Sat Dec 16 09:38:42 GMT 2023
|
PRIMARY | |||
|
73952216
Created by
admin on Sat Dec 16 09:38:42 GMT 2023 , Edited by admin on Sat Dec 16 09:38:42 GMT 2023
|
PRIMARY |